GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

Vectus Biosystems VBS.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.08

+8.57%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Vectus Biosystems — daily ASX:VBS

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Vectus Biosystems on TradingView ↗
Market value
A$4.1m
Last close × shares
Volume
125.3k
Shares, 9 Nov 2026
Price to earnings
2.4

About Vectus Biosystems

Its shares trade on ASX under the ticker VBS.AX. It has been listed since 23 February 2016. In the fiscal year to 30 June 2025, it reported revenue of A$478,182 and a net loss of A$1.8m. At that date it held total assets of A$782,656 and shareholders' equity of −A$256,622.

Vectus Biosystems Ltd. operates as a drug discovery and development company. The company is headquartered in Rosebery, New South Wales. The company went IPO on 2016-02-23. The firm focuses on medical research and development. The company is engaged in developing a treatment for fibrosis and high blood pressure, which includes the treatment for diseases in the fibrotic market, namely heart, kidney, and liver diseases. Its compound, VB0004, focuses on treating the hardening of functional tissue and high blood pressure. The company also focuses on developing candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH) as well as pulmonary fibrotic diseases. The firm has also developed technology focused at improving the speed and accuracy of measuring the amount of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in samples tested in laboratories. Accugen is a platform, developed by its wholly owned subsidiary, Accugen Pty Limited, comprising of reagents, and software that quantitate polymerase chain reaction (qPCR) reactions.

Figures and description from our data supplier, not checked against the company's own report.

More about Vectus Biosystems →

Latest on Vectus Biosystems

Our reporting

We have not reported on Vectus Biosystems yet.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Vectus Biosystems's ticker?

Vectus Biosystems trades as VBS.AX on ASX, under ISIN AU000000VBS9.

What was Vectus Biosystems's last closing price?

0.08 on 9 Nov 2026. The figure is in AUD and is never converted.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.